Kamada (NASDAQ:KMDA) Stock Crosses Above Two Hundred Day Moving Average – What’s Next?

Kamada Ltd. (NASDAQ:KMDA) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.03 and traded as high as $7.85. Kamada shares last traded at $7.63, with a volume of 147,183 shares.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Kamada in a report on Friday, January 10th.

Kamada Price Performance

The firm has a market capitalization of $438.57 million, a price-to-earnings ratio of 27.25, a PEG ratio of 0.98 and a beta of 0.99. The business’s fifty day simple moving average is $6.88 and its 200 day simple moving average is $6.03.

Institutional Investors Weigh In On Kamada

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. acquired a new stake in Kamada in the fourth quarter worth $67,000. Public Employees Retirement System of Ohio acquired a new position in shares of Kamada during the third quarter valued at about $77,000. Plato Investment Management Ltd acquired a new position in shares of Kamada during the third quarter valued at about $117,000. NewEdge Advisors LLC grew its holdings in shares of Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 8,260 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 1,549 shares during the last quarter. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.